Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025
Provided By GlobeNewswire
Last update: Apr 23, 2025
SAN MATEO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that three poster presentations featuring additional analyses from the Phase 2b FASCINATE-2 study of denifanstat in MASH will be presented at the European Association for the Study of Liver (EASL) Congress 2025 being held May 7-10, 2025 in Amsterdam, Netherlands.
Read more at globenewswire.com7.4
-0.87 (-10.52%)
Find more stocks in the Stock Screener
SGMT Latest News and Analysis
5 days ago - ChartmillHere are the top movers in Thursday's session.Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
13 days ago - ChartmillThese stocks are moving in today's pre-market sessionAs we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
